173 related articles for article (PubMed ID: 36717968)
1. Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?
Calvete O; Mestre J; Durmaz A; Gurnari C; Maciejewski JP; Solé F
Br J Haematol; 2023 Apr; 201(1):e5-e11. PubMed ID: 36717968
[No Abstract] [Full Text] [Related]
2. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.
Schratz KE; DeZern AE
Hematol Oncol Clin North Am; 2020 Apr; 34(2):333-356. PubMed ID: 32089214
[TBL] [Abstract][Full Text] [Related]
3. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
4. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
5. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Tawana K; Drazer MW; Churpek JE
Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
[TBL] [Abstract][Full Text] [Related]
6. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.
Padron E; Ball MC; Teer JK; Painter JS; Yoder SJ; Zhang C; Zhang L; Moscinski LC; Rollison DE; Gore SD; Bejar R; Walter MJ; Sekeres MA; Komrokji RS; Epling-Burnette PK
Blood; 2018 May; 131(21):2402-2405. PubMed ID: 29661788
[No Abstract] [Full Text] [Related]
7. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
8. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
9. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes.
Killick SB; Wiseman DH; Quek L; Cargo C; Culligan D; Enright H; Green S; Ingram W; Jones GL; Kell J; Krishnamurthy P; Kulasekararaj A; Mills J; Mufti G; Payne EM; Raghavan M; Stanworth SJ; Sternberg A; Bowen D;
Br J Haematol; 2021 Jul; 194(2):282-293. PubMed ID: 34137023
[No Abstract] [Full Text] [Related]
10. [Genetic predisposition to myelodysplastic syndrome/leukemia].
Hirabayashi S
Rinsho Ketsueki; 2021; 62(8):1029-1037. PubMed ID: 34497189
[TBL] [Abstract][Full Text] [Related]
11. A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia.
Braunstein EM; Li R; Sobreira N; Marosy B; Hetrick K; Doheny K; Gocke CD; Valle D; Brodsky RA; Cheng L
Leukemia; 2016 Nov; 30(11):2242-2245. PubMed ID: 27416908
[No Abstract] [Full Text] [Related]
12. Genetic predisposition to MDS: clinical features and clonal evolution.
Kennedy AL; Shimamura A
Blood; 2019 Mar; 133(10):1071-1085. PubMed ID: 30670445
[TBL] [Abstract][Full Text] [Related]
13. Genetic predisposition to MDS: diagnosis and management.
Furutani E; Shimamura A
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):110-119. PubMed ID: 31808839
[TBL] [Abstract][Full Text] [Related]
14. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
15. [Novel germline SAMD9 mutation in an elderly patient with myelodysplastic syndrome].
Uchida T; Fujii T; Ohara S; Imai Y; Inoue M; Harada Y; Harada H; Hagihara M
Rinsho Ketsueki; 2022; 63(8):865-869. PubMed ID: 36058856
[TBL] [Abstract][Full Text] [Related]
16. Myeloid Neoplasms with Germline Predisposition: A New Provisional Entity Within the World Health Organization Classification.
Czuchlewski DR; Peterson LC
Surg Pathol Clin; 2016 Mar; 9(1):165-76. PubMed ID: 26940275
[TBL] [Abstract][Full Text] [Related]
17. Rare germline variant contributions to myeloid malignancy susceptibility.
Li ST; Wang J; Wei R; Shi R; Adema V; Nagata Y; Kerr CM; Kuzmanovic T; Przychodzen B; Sole F; Maciejewski JP; LaFramboise T
Leukemia; 2020 Jun; 34(6):1675-1678. PubMed ID: 31911633
[No Abstract] [Full Text] [Related]
18. [Progress in research of the pathogenesis of childhood MDS/MPN].
Yoshida K
Rinsho Ketsueki; 2018; 59(10):2284-2289. PubMed ID: 30305537
[TBL] [Abstract][Full Text] [Related]
19. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
McReynolds LJ; Yang Y; Yuen Wong H; Tang J; Zhang Y; Mulé MP; Daub J; Palmer C; Foruraghi L; Liu Q; Zhu J; Wang W; West RR; Yohe ME; Hsu AP; Hickstein DD; Townsley DM; Holland SM; Calvo KR; Hourigan CS
Leuk Res; 2019 Jan; 76():70-75. PubMed ID: 30578959
[TBL] [Abstract][Full Text] [Related]
20. [Predisposition and progression of myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
